EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adelsberg, B. R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Adelsberg, B. R
Evidence-Based Medicine 2004; 9:114
© 2004 BMJ Publishing Group Ltd.


Therapeutics

Review: allergen specific immunotherapies reduce symptoms, medication requirements, and bronchial hyper-reactivity in asthma

Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;(4):CD001186.

Q In patients with asthma, how do different allergen specific (AS) immunotherapies compare for reducing asthma symptoms, medication requirements, and improving bronchial hyper-reactivity (BHR)?

GP/FP/Primary care *****{star}{star} IM/Internal medicine *****{star}{star} Allergy ******{star} Respirology *****{star}{star} Immunology ******{star}

Key Words: asthma • desensitisation (immunologic)

The first 150 words of the full text of this article appear below.

METHODS
Data sources: Medline (1966 to December 2001), the Cochrane Airways Group trials register (up to June 2001), EMBASE/Excerpta Medica, CINAHL, Current Contents, abstracts of dissertations, and reference lists.

Study selection and assessment: studies in any language were selected if they were randomised controlled trials (RCTs) comparing AS immunotherapy with placebo, antigenically inactive controls, untreated controls, or inhaled steroids; or comparing house dust extract with placebo. Studies were assessed for methodological quality using the Jadad scale.

Outcomes: asthma symptoms, medication requirements, lung function (including peak expiratory flow rate, FEV1, and thoracic gas volume), non-specific BHR (to histamine or methacholine), and AS BHR.

MAIN RESULTS
75 RCTs met the selection criteria (n = 3506). Patients who received AS immunotherapy (particularly mite, pollen, and animal dander allergens) had greater symptomatic improvement, had reduced asthma medication requirements, and were less likely to develop increased non-specific or AS BHR than those who received placebo (tableGo. . . [Full text of this article]

Bernard R Adelsberg, MD

Hamden Internal Medicine Associates
Hamden, Connecticut, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.